drugset / Trial / NCT00413283
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
RandomizedParallel-groupDouble-blindSupportive care
Summary
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.
Timeline
- Start
- 2006-12
- Primary completion
- 2008-12
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romiplostim | Peptide | 250 ug | Subcutaneous |
| Subject | Romiplostim | Peptide | 500 ug | Subcutaneous |
| Subject | Romiplostim | Peptide | 750 ug | Subcutaneous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |